Genoskin to attend Boston-Paris Biotechnology Summit In order to better serve our American customers, Genoskin plans to set up a production unit in Boston in 2018. Our project has recently been selected by the NETVA program, which helps companies prepare for this strategic move. In May, we will attend the Boston-Paris Biotechnology Summit, an independent conference supported by a panel of biotech professionals from both sides of the
Every year, the MEDEF, France’s largest entrepreneurial organisation, sets up local conferences in an attempt to bring companies together under a predefined theme. This year, Genoskin was invited to the 7th Edition of the Entrepreneurial Event (Grande Tribune des Entrepreneurs) to contribute to the discussion on the role of CEOs in driving change. The widely attended conference was headed by Pierre Gataz, the MEDEF’s president (see
The NETVA (New Technology Venture Accelerator) program consists in a preparation and exposure to high-tech US markets for young innovative French companies. It is run by the Office for Science & Technology of the Embassy of France in the United States in three locations: Boston, San Francisco and Washington, DC. Each year, 15 French startups are selected though a national competition
Genoskin launches new OncoSkin® skin cancer model at Meet2Win Genoskin has developed a new skin cancer model for the in vitro study of melanoma. Patients who suffer from this highly dangerous type of skin cancer currently have limited therapeutic options when the cancer reaches metastasis. The OncoSkin® skin cancer model now enables in vitro studies on live melanoma spheroids implanted
Genoskin attended the 9th World Congress On Alternatives and Animal Use in The Life Sciences (WC9 2014) organized in Prague, Czech Republic, from the 24 to the 28 August. “The world congress provides an exceptional forum to underline the importance of both the ethical issues of animal experimentation and the approach to the life sciences in the 21st century.”